Time Frame |
[Not Specified]
|
Adverse Event Reporting Description |
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Arm/Group Title
|
Axitinib + Gemcitabine (Phase 1 Lead-In)
|
Axitinib + Gemcitabine
|
Gemcitabine
|
Arm/Group Description |
Axitinib (AG-013736) 5 milligram (m...
|
Axitinib (AG-013736) 5 mg tablet or...
|
Gemcitabine 1000 mg/m^2 30 minutes ...
|
Arm/Group Description |
Axitinib (AG-013736) 5 milligram (mg) tablet orally twice daily (BID) starting from Day 3 of Cycle 1, in cycles of 4 weeks. Gemcitabine 1000 milligram/square meter (mg/m^2) 30 minutes intravenous (IV) infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
|
Axitinib (AG-013736) 5 mg tablet orally twice daily (BID) from Day 1 of Cycle 1 (28 days) and all subsequent cycles (28 days). Gemcitabine 1000 mg/m^2 30-minute infusion on Day 1, 8 and 15 of each cycle.
|
Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
|
|
|
Axitinib + Gemcitabine (Phase 1 Lead-In)
|
Axitinib + Gemcitabine
|
Gemcitabine
|
|
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Total |
--/-- |
--/-- |
--/-- |
|
|
Axitinib + Gemcitabine (Phase 1 Lead-In)
|
Axitinib + Gemcitabine
|
Gemcitabine
|
|
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Total |
3/8 (37.50%) |
35/68 (51.47%) |
10/31 (32.26%) |
Blood and lymphatic system disorders |
|
|
|
Anaemia |
1/8 (12.50%) |
4/68 (5.88%) |
1/31 (3.23%) |
Disseminated intravascular coagulation |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Thrombocytopenia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Cardiac disorders |
|
|
|
Atrial fibrillation |
0/8 (0.00%) |
2/68 (2.94%) |
1/31 (3.23%) |
Atrial flutter |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Myocardial infarction |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Pericardial effusion |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Tachycardia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Ear and labyrinth disorders |
|
|
|
Tinnitus |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Gastrointestinal disorders |
|
|
|
Abdominal distension |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Abdominal pain |
0/8 (0.00%) |
5/68 (7.35%) |
0/31 (0.00%) |
Abdominal pain upper |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Abdominal strangulated hernia |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Colitis ischaemic |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Constipation |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Diarrhoea |
0/8 (0.00%) |
3/68 (4.41%) |
0/31 (0.00%) |
Duodenal obstruction |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Gastric haemorrhage |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Gastrointestinal haemorrhage |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Haematemesis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Intestinal ischaemia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Intestinal obstruction |
0/8 (0.00%) |
2/68 (2.94%) |
1/31 (3.23%) |
Melaena |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Nausea |
0/8 (0.00%) |
2/68 (2.94%) |
2/31 (6.45%) |
Oral pain |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Peritonitis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Pneumatosis intestinalis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Rectal haemorrhage |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Small intestinal haemorrhage |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Small intestinal obstruction |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Vomiting |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
General disorders |
|
|
|
Asthenia |
0/8 (0.00%) |
4/68 (5.88%) |
0/31 (0.00%) |
Chest pain |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Device occlusion |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Disease progression |
0/8 (0.00%) |
6/68 (8.82%) |
0/31 (0.00%) |
Fatigue |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
General physical health deterioration |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Pain |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Multi-organ failure |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Pyrexia |
0/8 (0.00%) |
1/68 (1.47%) |
3/31 (9.68%) |
Hepatobiliary disorders |
|
|
|
Cholangitis |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Cholestasis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Gallbladder obstruction |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Jaundice cholestatic |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Infections and infestations |
|
|
|
Empyema |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Enterobacter bacteraemia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Liver abscess |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Lower respiratory tract infection |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Lung abscess |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Lung infection |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Oral candidiasis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Pneumonia |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Sepsis |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Septic shock |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Infection |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Investigations |
|
|
|
Blood pressure increased |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Platelet count decreased |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Metabolism and nutrition disorders |
|
|
|
Cachexia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Dehydration |
0/8 (0.00%) |
3/68 (4.41%) |
2/31 (6.45%) |
Failure to thrive |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Hypocalcaemia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Hypokalaemia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Hyponatraemia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Hypophagia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Lactic acidosis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Nervous system disorders |
|
|
|
Convulsion |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Headache |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Neuromyopathy |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Syncope |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Transient ischaemic attack |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Psychiatric disorders |
|
|
|
Confusional state |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Mental status changes |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Renal and urinary disorders |
|
|
|
Renal impairment |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Respiratory, thoracic and mediastinal disorders |
|
|
|
Dyspnoea |
0/8 (0.00%) |
6/68 (8.82%) |
0/31 (0.00%) |
Epistaxis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Hypoxia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Pneumothorax |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Pulmonary embolism |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Vascular disorders |
|
|
|
Deep vein thrombosis |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Post thrombotic syndrome |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Thrombosis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Indicates events were collected by non-systematic assessment
Term from vocabulary, MedDRA v13.1
|
|
Frequency Threshold for Reporting Other Adverse Events
|
0%
|
|
Axitinib + Gemcitabine (Phase 1 Lead-In)
|
Axitinib + Gemcitabine
|
Gemcitabine
|
|
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Total |
7/8 (87.50%) |
67/68 (98.53%) |
26/31 (83.87%) |
Blood and lymphatic system disorders |
|
|
|
Anaemia |
4/8 (50.00%) |
16/68 (23.53%) |
7/31 (22.58%) |
Granulocytopenia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Iron deficiency anaemia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Leukopenia |
2/8 (25.00%) |
3/68 (4.41%) |
0/31 (0.00%) |
Neutropenia |
2/8 (25.00%) |
15/68 (22.06%) |
6/31 (19.35%) |
Thrombocytopenia |
4/8 (50.00%) |
10/68 (14.71%) |
2/31 (6.45%) |
Thrombocytosis |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Lymphopenia |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Cardiac disorders |
|
|
|
Atrial fibrillation |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Cardiogenic shock |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Cyanosis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Pericardial effusion |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Sinus tachycardia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Tachycardia |
0/8 (0.00%) |
1/68 (1.47%) |
2/31 (6.45%) |
Ear and labyrinth disorders |
|
|
|
Ear pain |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Tinnitus |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Vertigo |
1/8 (12.50%) |
1/68 (1.47%) |
0/31 (0.00%) |
Eye disorders |
|
|
|
Blepharitis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Conjunctivitis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Eyelid oedema |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Photopsia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Vitreous floaters |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Gastrointestinal disorders |
|
|
|
Abdominal discomfort |
1/8 (12.50%) |
0/68 (0.00%) |
2/31 (6.45%) |
Abdominal distension |
0/8 (0.00%) |
4/68 (5.88%) |
1/31 (3.23%) |
Abdominal hernia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Abdominal pain |
2/8 (25.00%) |
16/68 (23.53%) |
8/31 (25.81%) |
Abdominal pain upper |
1/8 (12.50%) |
11/68 (16.18%) |
1/31 (3.23%) |
Abdominal tenderness |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Aphthous stomatitis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Ascites |
1/8 (12.50%) |
3/68 (4.41%) |
5/31 (16.13%) |
Constipation |
2/8 (25.00%) |
18/68 (26.47%) |
7/31 (22.58%) |
Diarrhoea |
4/8 (50.00%) |
35/68 (51.47%) |
8/31 (25.81%) |
Dry mouth |
0/8 (0.00%) |
5/68 (7.35%) |
1/31 (3.23%) |
Duodenal ulcer |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Dyspepsia |
0/8 (0.00%) |
9/68 (13.24%) |
4/31 (12.90%) |
Dysphagia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Flatulence |
1/8 (12.50%) |
5/68 (7.35%) |
2/31 (6.45%) |
Gastric Ulcer |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Gastritis |
0/8 (0.00%) |
2/68 (2.94%) |
1/31 (3.23%) |
Gastrointestinal haemorrhage |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Gastrooesophageal reflux disease |
2/8 (25.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Gingival pain |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Gingival swelling |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Haematochezia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Haemorrhoids |
0/8 (0.00%) |
5/68 (7.35%) |
0/31 (0.00%) |
Inguinal hernia |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Intestinal haemorrhage |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Lip ulceration |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Mesenteric artery stenosis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Nausea |
3/8 (37.50%) |
30/68 (44.12%) |
15/31 (48.39%) |
Oral pain |
0/8 (0.00%) |
6/68 (8.82%) |
0/31 (0.00%) |
Peptic ulcer haemorrhage |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Proctalgia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Rectal haemorrhage |
0/8 (0.00%) |
2/68 (2.94%) |
1/31 (3.23%) |
Sensitivity of teeth |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Small intestinal obstruction |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Steatorrhoea |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Stomatitis |
1/8 (12.50%) |
12/68 (17.65%) |
2/31 (6.45%) |
Tongue coated |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Tongue disorder |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Toothache |
2/8 (25.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Vomiting |
2/8 (25.00%) |
29/68 (42.65%) |
12/31 (38.71%) |
General disorders |
|
|
|
Adverse drug reaction |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Asthenia |
1/8 (12.50%) |
22/68 (32.35%) |
4/31 (12.90%) |
Catheter site pain |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Chest pain |
1/8 (12.50%) |
5/68 (7.35%) |
0/31 (0.00%) |
Chills |
0/8 (0.00%) |
5/68 (7.35%) |
3/31 (9.68%) |
Device occlusion |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Disease progression |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Face oedema |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Fatigue |
7/8 (87.50%) |
29/68 (42.65%) |
10/31 (32.26%) |
Feeling cold |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
General physical health deterioration |
1/8 (12.50%) |
1/68 (1.47%) |
0/31 (0.00%) |
Hyperpyrexia |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Influenza like illness |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Infusion related reaction |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Infusion site pain |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Malaise |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Mass |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Mucosal dryness |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Mucosal inflammation |
3/8 (37.50%) |
12/68 (17.65%) |
2/31 (6.45%) |
Oedema |
0/8 (0.00%) |
6/68 (8.82%) |
0/31 (0.00%) |
Oedema peripheral |
1/8 (12.50%) |
11/68 (16.18%) |
8/31 (25.81%) |
Pain |
0/8 (0.00%) |
10/68 (14.71%) |
2/31 (6.45%) |
Performance status decreased |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Pyrexia |
1/8 (12.50%) |
12/68 (17.65%) |
7/31 (22.58%) |
Hepatobiliary disorders |
|
|
|
Bile duct obstruction |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Bile duct stenosis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Cholangitis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Cholecystitis |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Cholestasis |
1/8 (12.50%) |
1/68 (1.47%) |
1/31 (3.23%) |
Cytolytic hepatitis |
3/8 (37.50%) |
1/68 (1.47%) |
1/31 (3.23%) |
Hepatotoxicity |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Hyperbilirubinaemia |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Jaundice |
0/8 (0.00%) |
2/68 (2.94%) |
1/31 (3.23%) |
Immune system disorders |
|
|
|
Hypersensitivity |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Infections and infestations |
|
|
|
Bacteraemia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Bronchitis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Candidiasis |
0/8 (0.00%) |
2/68 (2.94%) |
1/31 (3.23%) |
Cellulitis |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Diverticulitis |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Escherichia sepsis |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Folliculitis |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Gastroenteritis |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Gingival abscess |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Herpes ophthalmic |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Hordeolum |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Infected skin ulcer |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Infection |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Influenza |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Localised infection |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Nasopharyngitis |
2/8 (25.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Oral candidiasis |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Oral herpes |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Oropharyngeal candidiasis |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Periodontal infection |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Pneumonia |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Staphylococcal infection |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Upper respiratory tract infection |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Urinary tract infection |
1/8 (12.50%) |
9/68 (13.24%) |
3/31 (9.68%) |
Vulvovaginal candidiasis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Wound infection |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Injury, poisoning and procedural complications |
|
|
|
Contusion |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Drug toxicity |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Excoriation |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Fall |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Joint sprain |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Muscle strain |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Periorbital haematoma |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Procedural pain |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Sunburn |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Investigations |
|
|
|
Alanine aminotransferase |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Alanine aminotransferase increased |
0/8 (0.00%) |
3/68 (4.41%) |
1/31 (3.23%) |
Aspartate aminotransferase |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Aspartate aminotransferase increased |
0/8 (0.00%) |
2/68 (2.94%) |
2/31 (6.45%) |
Blood albumin decreased |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Blood albumin increased |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Blood alkaline phosphatase |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Blood alkaline phosphatase increased |
0/8 (0.00%) |
2/68 (2.94%) |
1/31 (3.23%) |
Blood bilirubin increased |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Blood creatinine increased |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Blood glucose |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Blood glucose increased |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Blood lactate dehydrogenase increased |
1/8 (12.50%) |
1/68 (1.47%) |
0/31 (0.00%) |
Blood potassium decreased |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Blood pressure increased |
0/8 (0.00%) |
3/68 (4.41%) |
0/31 (0.00%) |
Blood sodium decreased |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Blood thyroid stimulating hormone increased |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Haemoglobin |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Haemoglobin decreased |
0/8 (0.00%) |
5/68 (7.35%) |
2/31 (6.45%) |
Heart rate increased |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
International normalised ratio |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Neutrophil count |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Neutrophil count decreased |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Platelet count decreased |
0/8 (0.00%) |
4/68 (5.88%) |
0/31 (0.00%) |
Prothrombin time prolonged |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Transaminases increased |
0/8 (0.00%) |
2/68 (2.94%) |
1/31 (3.23%) |
Weight decreased |
1/8 (12.50%) |
16/68 (23.53%) |
4/31 (12.90%) |
Metabolism and nutrition disorders |
|
|
|
Anorexia |
3/8 (37.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Cachexia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Decreased appetite |
1/8 (12.50%) |
29/68 (42.65%) |
10/31 (32.26%) |
Dehydration |
1/8 (12.50%) |
4/68 (5.88%) |
0/31 (0.00%) |
Diabetes mellitus inadequate control |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Failure to thrive |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Hyperglycaemia |
0/8 (0.00%) |
3/68 (4.41%) |
0/31 (0.00%) |
Hyperkalaemia |
0/8 (0.00%) |
2/68 (2.94%) |
2/31 (6.45%) |
Hypernatraemia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Hypoalbuminaemia |
1/8 (12.50%) |
2/68 (2.94%) |
0/31 (0.00%) |
Hypocalcaemia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Hypoglycaemia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Hypokalaemia |
0/8 (0.00%) |
11/68 (16.18%) |
4/31 (12.90%) |
Hypomagnesaemia |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Musculoskeletal and connective tissue disorders |
|
|
|
Arthralgia |
1/8 (12.50%) |
1/68 (1.47%) |
0/31 (0.00%) |
Back pain |
2/8 (25.00%) |
12/68 (17.65%) |
2/31 (6.45%) |
Bone pain |
1/8 (12.50%) |
2/68 (2.94%) |
0/31 (0.00%) |
Flank pain |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Joint swelling |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Mobility decreased |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Muscle atrophy |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Muscle spasms |
1/8 (12.50%) |
1/68 (1.47%) |
0/31 (0.00%) |
Muscular weakness |
1/8 (12.50%) |
3/68 (4.41%) |
0/31 (0.00%) |
Musculoskeletal chest pain |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Musculoskeletal pain |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Myalgia |
0/8 (0.00%) |
3/68 (4.41%) |
0/31 (0.00%) |
Myositis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Pain in extremity |
0/8 (0.00%) |
6/68 (8.82%) |
3/31 (9.68%) |
Spinal osteoarthritis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Trigger finger |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
|
|
Malignant pleural effusion |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Tumour pain |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Nervous system disorders |
|
|
|
Aphasia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Ataxia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Balance disorder |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Cerebral ischaemia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Dizziness |
0/8 (0.00%) |
8/68 (11.76%) |
3/31 (9.68%) |
Dysarthria |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Dysgeusia |
1/8 (12.50%) |
7/68 (10.29%) |
2/31 (6.45%) |
Dyskinesia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Facial paresis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Headache |
1/8 (12.50%) |
9/68 (13.24%) |
2/31 (6.45%) |
Hypoaesthesia |
0/8 (0.00%) |
5/68 (7.35%) |
0/31 (0.00%) |
Lethargy |
0/8 (0.00%) |
6/68 (8.82%) |
0/31 (0.00%) |
Neuropathy |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Neuropathy peripheral |
1/8 (12.50%) |
3/68 (4.41%) |
0/31 (0.00%) |
Paraesthesia |
1/8 (12.50%) |
1/68 (1.47%) |
1/31 (3.23%) |
Peripheral sensory neuropathy |
0/8 (0.00%) |
2/68 (2.94%) |
1/31 (3.23%) |
Sensory loss |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Somnolence |
0/8 (0.00%) |
2/68 (2.94%) |
1/31 (3.23%) |
Syncope |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Tremor |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Psychiatric disorders |
|
|
|
Agitation |
0/8 (0.00%) |
2/68 (2.94%) |
1/31 (3.23%) |
Anxiety |
0/8 (0.00%) |
9/68 (13.24%) |
3/31 (9.68%) |
Confusional state |
0/8 (0.00%) |
2/68 (2.94%) |
2/31 (6.45%) |
Delirium |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Depressed mood |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Depression |
2/8 (25.00%) |
7/68 (10.29%) |
2/31 (6.45%) |
Insomnia |
2/8 (25.00%) |
6/68 (8.82%) |
0/31 (0.00%) |
Restlessness |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Sleep disorder |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Renal and urinary disorders |
|
|
|
Chromaturia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Dysuria |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Haematuria |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Haemoglobinuria |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Nocturia |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Oliguria |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Proteinuria |
0/8 (0.00%) |
6/68 (8.82%) |
0/31 (0.00%) |
Renal failure acute |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Urinary incontinence |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Urinary retention |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Urine flow decreased |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Reproductive system and breast disorders |
|
|
|
Erectile dysfunction |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Metrorrhagia |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Vaginal haemorrhage |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Vulvovaginal dryness |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Vulvovaginal erythema |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Respiratory, thoracic and mediastinal disorders |
|
|
|
Cough |
2/8 (25.00%) |
5/68 (7.35%) |
3/31 (9.68%) |
Dyspnoea |
2/8 (25.00%) |
15/68 (22.06%) |
5/31 (16.13%) |
Dyspnoea exertional |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Epistaxis |
2/8 (25.00%) |
8/68 (11.76%) |
0/31 (0.00%) |
Haemoptysis |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Hiccups |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Nasal dryness |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Orthopnoea |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Pleural effusion |
0/8 (0.00%) |
3/68 (4.41%) |
1/31 (3.23%) |
Pleuritic pain |
0/8 (0.00%) |
1/68 (1.47%) |
1/31 (3.23%) |
Pneumonitis |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Pulmonary oedema |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Respiratory distress |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Rhinorrhoea |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Upper-airway cough syndrome |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Skin and subcutaneous tissue disorders |
|
|
|
Alopecia |
1/8 (12.50%) |
10/68 (14.71%) |
0/31 (0.00%) |
Decubitus ulcer |
0/8 (0.00%) |
4/68 (5.88%) |
0/31 (0.00%) |
Dry Skin |
1/8 (12.50%) |
0/68 (0.00%) |
0/31 (0.00%) |
Erythema |
0/8 (0.00%) |
2/68 (2.94%) |
1/31 (3.23%) |
Hyperhidrosis |
1/8 (12.50%) |
2/68 (2.94%) |
3/31 (9.68%) |
Livedo reticularis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Night sweats |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Palmar erythema |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Palmar-plantar erythrodysaesthesia syndrome |
2/8 (25.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Petechiae |
0/8 (0.00%) |
2/68 (2.94%) |
0/31 (0.00%) |
Photosensitivity reaction |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Pruritus |
2/8 (25.00%) |
6/68 (8.82%) |
1/31 (3.23%) |
Pruritus generalised |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Rash |
0/8 (0.00%) |
12/68 (17.65%) |
2/31 (6.45%) |
Rash generalised |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Skin lesion |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Urticaria |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Surgical and medical procedures |
|
|
|
Pancreaticoduodenectomy |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Vascular disorders |
|
|
|
Deep vein thrombosis |
0/8 (0.00%) |
4/68 (5.88%) |
2/31 (6.45%) |
Haemorrhage |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Hot flush |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Hypertension |
4/8 (50.00%) |
16/68 (23.53%) |
0/31 (0.00%) |
Pallor |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Shock |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Thrombophlebitis |
0/8 (0.00%) |
1/68 (1.47%) |
0/31 (0.00%) |
Thrombosis |
0/8 (0.00%) |
0/68 (0.00%) |
1/31 (3.23%) |
Indicates events were collected by non-systematic assessment
Term from vocabulary, MedDRA v13.1
|